STOCK TITAN
  1. Home
  2. News
  3. BTCY

Biotricity Inc - BTCY STOCK NEWS

Welcome to our dedicated news page for Biotricity (Ticker: BTCY), a resource for investors and traders seeking the latest updates and insights on Biotricity.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biotricity's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biotricity's position in the market.

News
Biotricity Launches Major Cardiac Monitoring Pilot Program in a Hospital System Comprised of 9 Hospitals and 10 Clinics
Rhea-AI Summary
Biotricity Inc. (BTCY) launches a groundbreaking cardiac monitoring pilot program in collaboration with a prestigious hospital group comprising 9 hospitals and 10 clinics. The program aims to optimize patient interaction protocols and streamline data collection processes, showcasing the impact of Biotricity's technology suite. This initiative follows strategic partnerships with leading Group Purchasing Organizations (GPOs) totaling $264 billion, providing access to 90% of hospitals nationwide. The CEO, Dr. Waqaas Al-Siddiq, emphasizes the transformative potential of their solutions in redefining disease profiling, patient management, and preventative care methodologies. With a focus on a $35 billion market opportunity, Biotricity is positioned as an innovative leader in healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Biotricity Launches Cardiac Monitoring Pilot Program with Major Hospital Network
Rhea-AI Summary
Biotricity Inc. (NASDAQ:BTCY) launches a cardiac monitoring pilot program with a major hospital network, spanning over 50 hospitals across multiple states. The program aims to showcase the value of Biotricity's solutions and potentially lead to a widespread commercial rollout. Dr. Waqaas Al-Siddiq, Biotricity's CEO, highlights the company's enhanced market reach through partnerships with Group Purchasing Organizations (GPOs) and emphasizes the scalability of their hardware and software solutions. The pilot program will focus on data collection, patient interaction protocols refinement, and technology suite enhancement to drive innovation in predictive monitoring tools and disease prevention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.45%
Tags
none
-
News
Biotricity Announces a Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities
Rhea-AI Summary
Biotricity Inc. announces a strategic partnership in neurology to conduct cardiac screenings, aiming to improve patient care and reduce costs. The company plans to build a broader cardiac screening network to support patients with co-morbidities, enhancing market reach within the healthcare industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
partnership
News
LOBO EV and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Rhea-AI Summary
RedChip Companies will feature interviews with LOBO EV Technologies and Biotricity, Inc. on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. LOBO EV, a Chinese EV manufacturer, offers a range of electric vehicles and software services, poised for growth in the $16 billion e-bike market. Biotricity, a leader in remote cardiac care, targets a $35 billion market with its innovative technology and strong market presence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
none
-
News
Biotricity Accelerates Market Access by Partnering with Third Major Group Purchasing Organization, Expanding Market Reach to 90% of U.S. Hospitals
Rhea-AI Summary
Biotricity Inc. (NASDAQ:BTCY) announces a strategic partnership with a leading Group Purchasing Organization (GPO) to enhance market reach and drive growth in the healthcare technology sector. The partnership grants access to 90% of all hospitals in the U.S., representing $264 billion in purchasing power. Biotricity aims to revolutionize healthcare with cutting-edge remote cardiac monitoring solutions, anticipating robust growth amid increasing healthcare expenditures and an aging population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
none
-
News
Biotricity Partners with Health Aid Africa to Provide Complementary Heart Health Screenings at Allegiant Stadium Concert
Rhea-AI Summary
Biotricity Inc. (BTCY) partners with Health Aid Africa for a charity concert to promote healthcare access and awareness. The event aims to revolutionize cardiac care, combining music, technology, and philanthropy on a global scale.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.55%
Tags
partnership
News
Biotricity Unveils that Improved Margins Resulted from Latest Advancements to its Proprietary Cardiac AI Cloud Platform and Announces Plans for Continued Expansion of its Cardiac AI Cloud
Rhea-AI Summary
Biotricity Inc. announces the expansion of its Cardiac AI platform, aiming to file for FDA clearance by the end of the year. The Healthcare AI Market is projected to reach $208.2 billion, with the remote patient monitoring market expected to hit $96.67 billion by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.91%
Tags
AI
-
News
Biotricity Partners with a Second Top Group Purchasing Organization - Positions Company for Expanded Market Access to 1 out of every 2 Hospitals in America
Rhea-AI Summary
Biotricity Inc. (BTCY) announces a strategic partnership with a top Group Purchasing Organization (GPO), expanding its market access to over 3,000 hospitals in the US with a purchasing power of $160 billion. This move highlights Biotricity's commitment to delivering cutting-edge healthcare solutions, driving positive clinical outcomes, and maximizing economic returns in the rapidly growing healthcare industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
News
Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Rhea-AI Summary
RedChip Companies will air interviews with Better Therapeutics, Inc. (Nasdaq:BTTX) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Better Therapeutics offers a groundbreaking approach to managing cardiometabolic diseases with its FDA-authorized product AspyreRx™, showcasing significant outcomes in treating type 2 diabetes. Biotricity revolutionizes cardiac care with remote diagnostic solutions, capturing an 8% market share in cardiology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
none
News
Biotricity Receives Health Canada Clearance for Biotres
Rhea-AI Summary
Biotricity Inc. (BTCY) receives Health Canada approval to enter the US $1.56 billion Canadian Cardiology Devices market, aiming to revolutionize cardiovascular health solutions. The approval of Biotres underscores the company's commitment to reshaping healthcare through innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.67%
Tags
none
Stock BTCY logo
Biotricity Inc

Nasdaq:BTCY

BTCY Rankings

#5311 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BTCY Stock Data

11.36M
7.88M
14.81%
3.93%
3.79%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Redwood City

About BTCY

biotricity is a medical technology company committed to improving healthcare by developing solutions that aid chronic disease prevention and management. biotricity’s premier product is bioflux, an ecg monitoring system that will be prescribed by physicians to diagnose and remotely monitor cardiac patients. biotricity is expanding medical-grade monitoring into the consumer market via its biolife solution, which empowers users to self-manage chronic conditions. biolife helps users make lifestyle changes by combining medically relevant ecg data with social media interactivity and a lifestyle log. biotricity’s r&d continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. the company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system.